Novartis’ Ianalumab Demonstrates Potential in Phase 3 Sjögren’s Syndrome Trials
Novartis' ianalumab has shown promise in Phase 3 clinical trials for the treatment of Sjögren's…
Autoimmune Diseases
Lupus Nephritis Relapse Risk Decreases with Low Disease Activity
New research reveals that patients with lupus nephritis who achieve low disease activity have a…